(6-Butyl-2-oxo-1,2-dihydro-pyridin-3-yl)-carbamic acid benzyl ester | 175211-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (6-Butyl-2-oxo-1,2-dihydro-pyridin-3-yl)-carbamic acid benzyl ester
• 英文别名: benzyl N-(6-butyl-2-oxo-1H-pyridin-3-yl)carbamate
• CAS: 175211-64-0
• 化学式: C₁₇H₂₀N₂O₃
• 分子量: 300.357
• InChiKey: WIYOQYFVHUUHSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (6-Butyl-2-oxo-1,2-dihydro-pyridin-3-yl)-carbamic acid benzyl ester 在 palladium on activated charcoal 氢气 、 sodium hydride 作用下， 生成 (3-Amino-6-butyl-2-oxo-2H-pyridin-1-yl)-acetic acid tert-butyl ester
  参考文献：
  名称：

  PYRIDONE-BASED PEPTIDOMIMETIC INHIBITORS OF INTERLEUKIN-1β-CONVERTING ENZYME (ICE)

  摘要：

  New potent, reversible inhibitors of recombinant human Interleukin-1 beta-converting enzyme (ICE, caspase-1) with significantly reduced peptide character are described. The compounds were designed by incorporation of pyridone and pyrimidone heterocyclic replacements for the P-2-P-3 amino acids of the native substrate and were optimised by manipulation of peripheral alkyl and aryl substituents. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00220-5
• 作为产物：
  描述：

  6-Butyl-3-cyano-2-pyridone 在 sodium hydroxide 、 叠氮磷酸二苯酯 、 氢溴酸 、 溶剂黄146 、 三乙胺 作用下， 生成 (6-Butyl-2-oxo-1,2-dihydro-pyridin-3-yl)-carbamic acid benzyl ester
  参考文献：
  名称：

  PYRIDONE-BASED PEPTIDOMIMETIC INHIBITORS OF INTERLEUKIN-1β-CONVERTING ENZYME (ICE)

  摘要：

  New potent, reversible inhibitors of recombinant human Interleukin-1 beta-converting enzyme (ICE, caspase-1) with significantly reduced peptide character are described. The compounds were designed by incorporation of pyridone and pyrimidone heterocyclic replacements for the P-2-P-3 amino acids of the native substrate and were optimised by manipulation of peripheral alkyl and aryl substituents. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00220-5

文献信息

• Inhibitors of interleukin-1 beta converting enzyme
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20020099042A1

  公开（公告）日：2002-07-25

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以优势地用作对白细胞介素-1介导的疾病，包括炎症性疾病、自身免疫疾病和神经退行性疾病的治疗剂。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法和治疗白细胞介素-1介导疾病的方法。
• INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME
  申请人：Bemis Guy W.

  公开号：US20120238749A1

  公开（公告）日：2012-09-20

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一类新型化合物，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可以优势地用作对抗白细胞介素-1介导的疾病，包括炎症性疾病、自身免疫性疾病和神经退行性疾病的药物。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法和治疗白细胞介素-1介导的疾病的方法。
• Inhibitors of interleukin-1beta converting enzyme
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1394175A1

  公开（公告）日：2004-03-03

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一类新型化合物，它们是白细胞介素-1β转换酶的抑制剂。本发明的 ICE 抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制 ICE 的活性，因此可作为抗白细胞介素-1 介导的疾病（包括炎症性疾病、自身免疫性疾病和神经退行性疾病）的药物。本发明还涉及抑制 ICE 活性的方法以及使用本发明化合物和组合物治疗白细胞介素-1 介导的疾病的方法。
• Inhibitors of interleukin-1Beta converting enzyme
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2123665A2

  公开（公告）日：2009-11-25

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一类新型化合物，它们是白细胞介素-1β转换酶的抑制剂。本发明的 ICE 抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制 ICE 的活性，因此可作为抗白细胞介素-1 介导的疾病（包括炎症性疾病、自身免疫性疾病和神经退行性疾病）的药物。本发明还涉及抑制 ICE 活性的方法以及使用本发明化合物和组合物治疗白细胞介素-1 介导的疾病的方法。
• Structure-based design of non-peptidic pyridone aldehydes as inhibitors of interleukin-1β converting enzyme
  作者：Julian M.C. Golec、Michael D. Mullican、Mark A. Murcko、Keith P. Wilson、David P. Kay、Stuart D. Jones、Robert Murdoch、Guy W. Bemis、Scott A. Raybuck、Yu-Ping Luong、David J. Livingston

  DOI：10.1016/s0960-894x(97)00394-6

  日期：1997.9

  Pyridone derivatives, especially with 6-aryl substituents, have been shown to be useful P-2-P-3 peptidomimetic scaffolds for the design of potent inhibitors of ICE. (C) 1997 Elsevier Science Ltd.